Iovance Biotherapeutics Inc
IOVA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.83B
Close$
$-0.19
102.9% downside
Current Fair Value
102.9% downsideOvervalued by 102.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.83 Billion |
|---|---|
| Enterprise Value | $2.77 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.69 |
| Outstanding Shares | 450,189,000 |
Return
| Return on Equity | -39.33% |
|---|---|
| Return on Assets | -31.62% |
| Return on Invested Capital | -35.73% |
Valuation & Multiples
| P/E Ratio | -9.06 |
|---|---|
| PEG | 15.72 |
| Price to Sales | - |
| Price to Book Ratio | 6.74 |
| Enterprise Value to Revenue | 8.51 |
| Enterprise Value to EBIT | -9.57 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$87.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$109.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0658▲ 49.82% |
|---|---|
| Total Calls | 3,160,411▲ 9.03% |
| Total Puts | 3,368,407▲ 104.72% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 64.27%▼ 0.00% |
|---|---|
| Total Invested | $943.36M▲ 31.88% |
| Investors Holding | 301▲ 26.00% |
ESG Score
No data
About Iovance Biotherapeutics Inc
CEO: Maria Fardis